We are live on ! Find out more
OC

Oppenheimer & Co Portfolio holdings

AUM $8.21B
1-Year Est. Return 28.81%
This Fund
S&P 500
This Quarter Est. Return
+2.6%
1 Year Est. Return
+28.81%
3 Year Est. Return
+92.54%
5 Year Est. Return
+114.67%
10 Year Est. Return
+429.8%
AUM
$3.34B
AUM Growth
+$209M
Cap. Flow
+$157M
Cap. Flow %
4.72%
Top 10 Hldgs %
12.01%
Holding
1,564
New
189
Increased
576
Reduced
529
Closed
163

Sector Composition

Rank Sector Weight
1 Energy 11.94%
2 Healthcare 10.62%
3 Industrials 9.8%
4 Technology 9.43%
5 Financials 9.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FBT icon
676
First Trust NYSE Arca Biotechnology Index Fund
FBT
$2.78B
$821K 0.02%
10,700
-550
-5% -$42.9K
IFLN
677
Invesco Bloomberg Enhanced Fallen Angels ETF
IFLN
$308M
$818K 0.02%
42,109
+5,261
+14% +$102K
WFM
678
DELISTED
Whole Foods Market Inc
WFM
$816K 0.02%
16,081
-1,341
-8% -$71.4K
FTR
679
DELISTED
Frontier Communications Corp.
FTR
$814K 0.02%
9,512
-2,967
-24% -$217K
FXG icon
680
First Trust Consumer Staples AlphaDEX Fund
FXG
$229M
$813K 0.02%
22,048
+4,542
+26% +$162K
AMP icon
681
Ameriprise Financial
AMP
$48.3B
$809K 0.02%
7,351
FIS icon
682
Fidelity National Information Services
FIS
$23.1B
$802K 0.02%
15,012
+338
+2% +$18K
AUY
683
DELISTED
Yamana Gold, Inc.
AUY
$802K 0.02%
91,306
+24,685
+37% +$239K
AVP
684
DELISTED
Avon Products, Inc.
AVP
$800K 0.02%
54,651
+360
+0.7% +$5.53K
ARUN
685
DELISTED
ARUBA NETWORKS, INC.
ARUN
$797K 0.02%
+42,500
New +$851K
VXF icon
686
Vanguard Extended Market ETF
VXF
$30.3B
$782K 0.02%
9,198
-128
-1% -$10.7K
CBST
687
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$778K 0.02%
10,643
-5,599
-34% -$417K
SHW icon
688
Sherwin-Williams
SHW
$82.7B
$776K 0.02%
11,805
-189
-2% -$12.2K
FCH
689
DELISTED
Felcor Lodging Trust
FCH
$775K 0.02%
85,715
-7,866
-8% -$66.9K
LAZ icon
690
Lazard
LAZ
$4.13B
$772K 0.02%
+16,390
New +$738K
CINF icon
691
Cincinnati Financial
CINF
$27.3B
$771K 0.02%
15,851
+924
+6% +$44.5K
CPA icon
692
Copa Holdings
CPA
$5.76B
$769K 0.02%
5,297
-212
-4% -$29.5K
HIMX
693
Himax Technologies
HIMX
$2.19B
$767K 0.02%
66,514
-2,975
-4% -$41.4K
ARMH
694
DELISTED
ARM HOLDINGS PLC ADS
ARMH
$767K 0.02%
15,052
+1,710
+13% +$83.1K
NWL icon
695
Newell Brands
NWL
$2.38B
$763K 0.02%
25,549
+5,585
+28% +$173K
EFG icon
696
iShares MSCI EAFE Growth ETF
EFG
$16.6B
$757K 0.02%
10,665
-23,589
-69% -$1.65M
FTSL icon
697
First Trust Senior Loan Fund ETF
FTSL
$2.32B
$747K 0.02%
15,036
+349
+2% +$17.4K
ECYT
698
DELISTED
Endocyte, Inc. Common Stock
ECYT
$745K 0.02%
+31,300
New +$454K
XXIA
699
DELISTED
Ixia
XXIA
$741K 0.02%
59,284
+10,877
+22% +$139K
MT icon
700
ArcelorMittal
MT
$52.9B
$740K 0.02%
20,030
+1,312
+7% +$48.8K

Similar funds

Oppenheimer & Co's Q1 2014 Portfolio in Review

As of Q1 2014, Oppenheimer & Co held 1,564 positions worth $3.34B, up 6.7% from $3.13B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Oppenheimer & Co deployed $157M of net new capital in Q1 2014, opening 189 new positions and adding to 576 existing holdings. Its largest new stake was Vanguard Morningstar Total Stock Market ETF: 169,083 shares worth $16.5M.

By sector, the portfolio is most concentrated in Energy at 12% of assets, down from 12% a quarter earlier, followed by Healthcare and Industrials.

On the sell side, the largest reduction was Vanguard Dividend Appreciation ETF, an estimated $7.79M trimmed.

  • Oppenheimer & Co's largest Q1 2014 buy was Vanguard Morningstar Total Stock Market ETF: 169,083 shares worth $16.5M.
  • Oppenheimer & Co added most to Monsanto Co in Q1 2014, an estimated $30M increase.
  • Oppenheimer & Co's biggest Q1 2014 reduction was Vanguard Dividend Appreciation ETF, cutting an estimated $7.79M.
  • Oppenheimer & Co fully exited TetraLogic Pharmaceuticals Corporation in Q1 2014, selling an estimated $10.2M.
  • Oppenheimer & Co's ten largest holdings make up 12% of its $3.34B portfolio in Q1 2014.
  • Oppenheimer & Co opened 189 new positions and closed 163 in Q1 2014.
  • Oppenheimer & Co's portfolio value rose 6.7% quarter-over-quarter to $3.34B.

Based on Oppenheimer & Co's 13F filing for Q1 2014, filed 9 May 2014.